For Consumers

Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender

Sex differences may influence susceptibility to substance abuse, which could have implications for optimal prevention and treatment. Gender influences also impact public health from an environmental perspective. To identify and treat women most at risk, researchers, educators, and clinicians must be able to recognize and consider both sex and gender differences.

The U.S. Food and Drug Administration’s Office of Women’s Health, in collaboration with the Center for Drug Evaluation and Research and the Center for Tobacco Products, will be hosting a 2-day public meeting, “Scientific Conference: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender,” to address this important issue. The conference will include presentations by experts in the field of opioid and tobacco research, professional education, and clinical care on the biological (sex) and sociological (gender) influences on use, misuse, and recovery.

Keynote Speakers

Day 1

Commissioner Scott Gottlieb, MD

Scott Gottlieb, M.D.
Commissioner of Food and Drugs

Day 2

VADM Jerome M. Adams, M.D., M.P.H.

VADM Jerome M. Adams, M.D., M.P.H.
U.S. Surgeon General

To view this meeting online via webcast, and to attend in-person, you must register at:

https://fda-opioidnicotinemeeting.eventbrite.com disclaimer icon

When: Thursday, September 27, 2018, and Friday, September 28, 2018, from 8:30 a.m. - 4:00 p.m.

Where: FDA’s White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503-A), Silver Spring, MD 20993.

About Public Meetings at the FDA White Oak Campus

Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender

Executive Steering Committee (ESC)
Committee Member Title
Ami Bahde, MPHProgram Analyst, FDA CTP
Terri Cornelison, MD, PhD, FACOGAssistant Director for the Health of Women, FDA CDRH
Carolyn Dresler, MD, MPA Associate Director For Medical and Health Sciences, FDA CTP
Marjorie Jenkins, MD, MEdHP, FACPDirector of Medical Initiatives and Scientific Engagement, FDA OWH
Tamra Meyer, PhD, MPH Lead Epidemiologist, FDA CDER OSE 
Pamela Scott, PhD Deputy Director, Office of Women's Health; Director of Research and Development, FDA OWH 
Jessica Tytel, MPH Senior Advisor, HHS OWH 
Rita Valentino, PhD Director, Division of Neuroscience and Behavior, NIH NIDA 
Cora Lee Wetherington, PhD Women & Sex/Gender Differences Research Coordinator, NIH NIDA
Celia Winchell, MD Medical Officer Team Leader (addiction, drugs), FDA CDER DAAAP 

 

Scientific Planning Committee (SPC)
Committee Member Title
Lori Bastian, MD, MPHProfessor of Internal Medicine (General Medicine);
Section Chief of General Internal Medicine, VA Connecticut Healthcare System;
Director, Pain Research, Informatics, Multimorbidities, and Education (PRIME) Center
Jill Becker, PhDResearch Professor, Department of Psychiatry, Molecular and
Behavioral Neuroscience Institute, University of Michigan
Michele Bloch, MD, PhDChief, Tobacco Control Research Branch, Behavioral Research Program, NIH NCI
Kathleen Brady, MD, PhDDistinguished University Professor, Associate Provost, Clinical and Translational Science;
Director, South Carolina Clinical and Translational Research Institute (SCTR),
Medical University of South Carolina
Terri Cornelison, MD, PhD, FACOGAssistant Director for the Health of Women, FDA CDRH
Carolyn Dresler, MD, MPA Associate Director for Medical and Health Sciences, FDA CTP
Phyllis E. Greenberger, MSWSenior VP of Science and Health Policy, Healthy Women
Gioia Guerrieri, DOMedical Officer, CDER DAAAP
Amber Jessup, PhDSenior Economist, HHS ASPE
Marjorie Jenkins, MD, MEdHP, FACPDirector of Medical Initiatives and Scientific Engagement, FDA OWH
Hendrée Jones, PhDProfessor, Department of Obstetrics and Gynecology;
Executive Director of UNC Horizons, University of North Carolina Chapel Hill School of Medicine
Karin Mack, PhDScience Officer, CDC 
Sherry McKee, PhDProfessor of Psychiatry; Director, Yale Behavioral Pharmacology Laboratory;
Clinical Director, Forensic Drug Diversion Clinic;
Director, Yale-SCOR to Develop Gender-Sensitive Therapeutics for Addiction
Yale University School of Medicine 
Chad D. Morris, PhDAssociate Professor, Department of Psychiatry,
Director of the Behavioral Health and Wellness Program,
Co-Director of the Wellness Leadership Institute, University of Colorado 
Judith (Jodi) Prochaska, PhD, MPHAssociate Professor, Department of Medicine, Stanford University 
Jane Segebrecht, MPHPublic Health Analyst, Team Lead, HHS HRSA 
Sayeedha Uddin, MD, MPHSenior Public Health Analyst, HHS OWH 
Cora Lee Wetherington, PhDWomen & Sex/Gender Differences Research Coordinator, NIH NIDA 
Jessica White, MPPSocial Science Analyst and CDC Team Lead, Division of Science Policy, HHS ASPE 
Scott Winiecki, MDLead Medical Officer, FDA CDER PASE 

 

Page Last Updated: 08/14/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English